Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 May;68(3):193–204. doi: 10.1016/j.curtheres.2007.06.004

Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study

Sung-Bae Kim 1, Jung Shin Lee 1, Heung Tae Kim 2, Yong Hyuck Im 3, Tae Won Kim 1, Baek Yeol Ryoo 2, Yeon Hee Park 2, Joon Oh Park 3, Keunchil Park 3,5, Hitoshi Katoh 4, Minoru Yamamoto 4
PMCID: PMC3967285  PMID: 24683210

Abstract

Abstract

Background:

Incadronate has been found to lessen the increase in corrected serum calcium levels in malignancy-associated hypercalcemia (MAH) in a Phase III study in Japan. The drug is currently used to treat MAH in Japan.

Objective:

The purpose of this study was to assess the clinical usefulness of incadronate in patients with MAH.

Methods:

This open-label study was conducted at 3 medical institutions in Korea. Korean patients with MAH (corrected serum calcium levels ≥11.0 mg/dL) were given a single 10-mg IV infusion of incadronate over 2 to 4 hours in 500 to 1000 mL of normal saline. Corrected calcium levels were determined and subjective symptoms and objective findings (ie, bone pain, spontaneous pain, pain from contusion, tenderness, other pain, loss of appetite, nausea and/or vomiting, thirst, constipation, fatigue, and disturbance of consciousness) were used to monitor the effectiveness of the drug for 6 days after the infusion. Symptoms were evaluated using a 4-point scale (0 = none to 3 = severe). Adverse events (AEs) were identified by patients' reports, and adverse drug events (ADEs) were assessed by the investigators throughout the study.

Results:

Twenty-four Korean patients (18 [75%]male, 6 [25%]female; mean age, 56.5 years) were included in the study; data from 22 and 24 patients were used to assess effectiveness and tolerability, respectively. Corrected serum calcium level was significantly decreased on day 6 after treatment compared with pretreatment on day 0 (baseline) (9.51 [0.89] mg/dL vs 11.83 [0.89] mg/dL; P < 0.001). The antihypercalcemic effect of incadronate became apparent as an inhibition of bone absorption a few days after infusion. Corrected serum calcium level was significantly decreased on days 2 to 6 (P < 0.001) after treatment compared with pretreatment at baseline. Evaluation of symptoms showed significant improvement in the incadronate-treated group (mean total score [range] at baseline, 8 [1–23] and day 6, 5.5 [1–17]; P = 0.001). Eight (33.3%) of the patients were found to have ADEs. Some of the 8 patients experienced >1 ADE (mild and transient fever [13 events], chills [3], headache [1], and myalgia [1]). AEs were observed in 19 (79.2%) of 24 patients. The most frequently reported AE was fever (14 events).

Conclusion:

In this small, open-label study, Korean subjects with MAH treated with incadronate experienced significant improvement in symptoms and calcium levels from baseline.

Key Words: incadronate, bisphosphonate, malignancy-associated hypercalcemia, Korea

Full Text

The Full Text of this article is available as a PDF (732.6 KB).

References

  • 1.Muggia FM. Overview of cancer-related hypercalcemia: Epidemiology and etiology. Semin Oncol. 1990;17(Suppl 5):3–9. [PubMed] [Google Scholar]
  • 2.Fleisch H. Bisphosphonate: Mechanism of action and clinical applications. In: Peck WA, editor. Bone and Mineral Research. Annual 1. Elsevier Science Pub. Co; New York, NY: 1982. pp. 319–357. [Google Scholar]
  • 3.Hotte SJ, Webert KE, Major PP. Zoledronic acid: An over view of its current and potential benefits in patients with malignancy. Todays Therapeutic Trends. 2002;20:197–219. [Google Scholar]
  • 4.Boonekamp PM, Lowik CW, van der Wee-Pals LJ. Enhancement of the inhibitory action of APD on the transformation of the osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner. 1987;2:29–42. [PubMed] [Google Scholar]
  • 5.Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986;1:27–39. [PubMed] [Google Scholar]
  • 6.Takahashi K, Fukushima S, Kokubo S. Effect of YM175 on hypercalcemia induced by human oral squamous cell carcinoma cells (in Japanese, English abstract) Kurinikaru Sutadi (Clinical Study) 1994;28:83–97. [Google Scholar]
  • 7.Ogata E, Tei M. Phase I clinical study of YM175, a new bone resorption inhibitor, by single intravenous administration in healthy male adults. Jpn Pharmacol Ther. 1994;22:181–210. [Google Scholar]
  • 8.Matsumoto T, Takebe K, Onaya T. Early phase II study of YM175 in patients with malignancy-associated hypercalcemia (in Japanese) Shindan To Chiryo. 1994;82:153–165. [Google Scholar]
  • 9.Matsumoto T, Takebe K, Ishii J, Nagata N. Dose finding study of YM175 in malignancy-associated hypercalcemia. Jpn J Clin Exp Med. 1994;71:237–254. [Google Scholar]
  • 10.Matsumoto T, Nagata N, Horikoshi N. Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia. J Int Med Res. 2002;30:230–243. doi: 10.1177/147323000203000303. [DOI] [PubMed] [Google Scholar]
  • 11.Thiebaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med. 1990;150:2125–2128. doi: 10.1001/archinte.1990.00390210095021. [DOI] [PubMed] [Google Scholar]
  • 12.Sato M, Hattori M, Tomita A. Comparative clinical study of alendronate injection with elcatonin in malignancy-associated hypercalcemia patients. Rinshou Iyaku. 1994;10:2667–2689. [Google Scholar]
  • 13.Matsumoto T, Fujita T, Morii H. Dose finding studies of pamidronate disodium in malignancy-associated hypercalcemia patients. Rinshou Iyaku. 1992;8:605–629. [Google Scholar]
  • 14.Portale AA. Blood calcium, phosphorus and magnesium. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Lippincott, Williams & Wilkins; Philadelphia, Pa: 1999. pp. 115–118. [Google Scholar]
  • 15.Tsai KS, Hsu SH, Yang RS. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women. Calcif Tissue Int. 1999;64:384–388. doi: 10.1007/pl00005819. [DOI] [PubMed] [Google Scholar]
  • 16.Hanson DA, Weis MA, Bollen AM. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992;7:1251–1258. doi: 10.1002/jbmr.5650071119. [DOI] [PubMed] [Google Scholar]
  • 17.Nakamura E, Imazaki H, Usui T. Metabolism of YM175. Distribution and excretion by intravenous administration of 14C-YM175 in rats. Yakubutsu Taisha. 1995;9:835–847. [Google Scholar]
  • 18.Usui T, Watanabe T, Higuchi S. Determination of a new bisphosphonate, YM175, in plasma, urine and bone by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1992;584:213–220. doi: 10.1016/0378-4347(92)80578-e. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES